Company / R&D Expense
Aspira Women's Health Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$2.9M
FY2025
5-year range
$2.9M / $5.9M
FY2021-FY2025
Trend
-11.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 3 consecutive years, from $6M in FY2022 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of +6.5%.
Declined from $4M to $3M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -21.4%
- 5-Year CAGR
- +6.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Aspira Women's Health Inc.'s r&d expense has declined for 3 consecutive years.
- 5-year CAGR of +6.5%, indicating consistent growth.
- In FY2025, r&d expense decreased 11.9% year-over-year.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -89.08 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.9M | -11.9% |
| FY2024 | $3.3M | -19.1% |
| FY2023 | $4.0M | -31.8% |
| FY2022 | $5.9M | +11.3% |
| FY2021 | $5.3M | +152.6% |
| FY2020 | $2.1M | +106.7% |
| FY2019 | $1.0M | +85.1% |
| FY2018 | $550.0K | -34.3% |
| FY2017 | $837.0K | -61.5% |
| FY2016 | $2.2M | -42.1% |